Research Papers

25 of 522 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activ…
Beredaki MI; Arendrup MC; Andes D; Meletiadis J.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Exploring the epidemiology of mcr genes, genetic context and plasmids in Enterobacteriaceae originating from pigs and h…
Leangapichart T; Stosic MS; Hickman RA; Lunha K; Jiwakanon J; Angkititrakul S; Magnusson U; Van Boeckel TP; Järhult JD; Sunde M.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Data Funding Declared
Trends in antibiotic selection pressure generated in primary care and their association with sentinel antimicrobial res…
Sijbom M; Büchner FL; Saadah NH; Numans ME; De Boer MGJ.
J Antimicrob Chemother (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Point prevalence audit surveys of respiratory tract infection consultations and antibiotic prescribing in primary care …
Shah M; Fleming A; Barbosa TM; van der Velden AW; Parveen S; Vellinga A.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration …
Jansen AME; Ter Heine R; Donnelly JP; Blijlevens N; Brüggemann RJM.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Health outcomes of penicillin allergy testing in children: a systematic review.
Kwok M; Heard KL; May A; Pilgrim R; Sandoe J; Tansley S; Scott J.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Registered Funding Declared
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
Ewoldt TMJ; Bahmany S; Abdulla A; Muller AE; Endeman H; Koch BCP.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam ag…
Igarashi Y; Takemura W; Liu X; Kojima N; Morita T; Chuang VTG; Enoki Y; Taguchi K; Matsumoto K.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020-21: outbre…
Moreno-Mingorance A; Mir-Cros A; Goterris L; Rodriguez-Garrido V; Sulleiro E; Barberà MJ; Alberny M; Hoyos-Mallecot Y; Descalzo V; Bravo A; Roca-Grande J; Viñado B; Pumarola T; Larrosa MN; González-López JJ.
J Antimicrob Chemother (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Transiently silent acquired antimicrobial resistance: an emerging challenge in susceptibility testing.
Wagner TM; Howden BP; Sundsfjord A; Hegstad K.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Awareness of antibiotic resistance: a tool for measurement among human and animal health care professionals in LMICs an…
Pinto Jimenez C; Pearson M; Hennessey M; Nkereuwem E; Crocker C; Egbujo U; Hendriks J; Smith S; Whanpuch P; Manongi R; Thi Hoa N; Chandler CIR.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
An extensively validated whole-cell biosensor for specific, sensitive and high-throughput detection of antibacterial in…
Galarion LH; Mitchell JK; Randall CP; O'Neill AJ.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.
Asempa TE; Kuti JL; Nascimento JC; Pope SJ; Salerno EL; Troy PJ; Nicolau DP.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of i…
Al Janabi J; Tevell S; Sieber RN; Stegger M; Söderquist B.
J Antimicrob Chemother (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Prevalence and characterization of piperaquine, mefloquine and artemisinin derivatives triple-resistant Plasmodium falc…
Mairet-Khedim M; Roesch C; Khim N; Srun S; Bouillon A; Kim S; Ke S; Kauy C; Kloeung N; Eam R; Khean C; Kul C; Chy S; Leang R; Ringwald P; Barale JC; Witkowski B.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isola…
Vallée M; Harding C; Hall J; Aldridge PD; Tan A.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Abbott IJ; van Gorp E; Cottingham H; Macesic N; Wallis SC; Roberts JA; Meletiadis J; Peleg AY.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison o…
Bishop EJ; Tiruvoipati R.
J Antimicrob Chemother (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy…
Hocqueloux L; Lefeuvre S; Bois J; Brucato S; Alix A; Valentin C; Peyro-Saint-Paul L; Got L; Fournel F; Dargere S; Prazuck T; Fournier A; Gregoire N; McNicholl I; Parienti JJ.
J Antimicrob Chemother (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
EnvR is a potent repressor of acrAB transcription in Salmonella.
Blair JMA; Siasat P; McNeil HE; Colclough A; Ricci V; Lawler AJ; Abdalaal H; Buckner MMC; Baylay A; Busby SJ; Piddock LJV.
J Antimicrob Chemother (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
A high-efficiency scar-free genome-editing toolkit for Acinetobacter baumannii.
de Dios R; Gadar K; McCarthy RR.
J Antimicrob Chemother (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis.
Sprute R; Grothe JH; Heringer S; Cornely OA.
J Antimicrob Chemother (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Frequency of drug-induced liver injury in children receiving anti-staphylococcal penicillins.
Tang K; Coombs S; Gwee A.
J Antimicrob Chemother (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
High frequency of increased triclosan MIC among CC5 MRSA and risk of misclassification of the SCCmec into types.
Viana AS; Botelho AMN; Feder A; Moustafa AM; Santos Silva DN; Martini CL; Ferreira ALP; Silva-Carvalho MC; Ferreira-Carvalho BT; Planet PJ; Sá Figueiredo AM.
J Antimicrob Chemother (Unknown)
Published: 2022
3/6 Transparent
Funding Declared